# OnCo record primary-myelofibrosis (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/primary-myelofibrosis/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "primary-myelofibrosis" ;
  schema:name "Primary myelofibrosis"@en ;
  schema:alternateName "PMF"@en, "Myelofibrosis"@en, "Chronic idiopathic myelofibrosis"@en, "Agnogenic myeloid metaplasia"@en, "Post-PV and post-ET myelofibrosis (secondary myelofibrosis)"@en ;
  schema:description "Primary myelofibrosis is a blood cancer in which the marrow scars over, the spleen swells and patients become anaemic and exhausted. JAK inhibitors, ruxolitinib first (COMFORT) and then fedratinib, pacritinib and momelotinib (MOMENTUM), shrink the spleen and relieve symptoms; only a donor stem cell transplant can cure it."@en ;
  schema:url <https://onco.cc/cancers/primary-myelofibrosis/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Primary_myelofibrosis> ;
  schema:citation <https://en.wikipedia.org/wiki/Primary_myelofibrosis>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1477> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/transfusion-support/> ;
  onco:targets <https://onco.cc/targets/jak2/> ;
  onco:terms <https://onco.cc/terms/jak2-v617f/>, <https://onco.cc/terms/post-pv-myelofibrosis/>, <https://onco.cc/terms/anaemia/>, <https://onco.cc/terms/allogeneic-transplant/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/>, <https://onco.cc/key-papers/paper-momentum-momelotinib-lancet-2023/> ;
  onco:pipeline <https://onco.cc/drugs/momelotinib/>, <https://onco.cc/drugs/pacritinib/>, <https://onco.cc/drugs/navitoclax/>, <https://onco.cc/drugs/pelabresib/>, <https://onco.cc/drugs/imetelstat/>, <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/trials/nct04468984/>, <https://onco.cc/trials/nct04717414/>, <https://onco.cc/trials/nct04576156/>, <https://onco.cc/trials/nct04562389/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:standardOfCare <https://onco.cc/drugs/aspirin/>, <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/drugs/ropeginterferon-alfa-2b/>, <https://onco.cc/drugs/peginterferon-alfa-2b/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/fedratinib/>, <https://onco.cc/drugs/pacritinib/>, <https://onco.cc/drugs/momelotinib/>, <https://onco.cc/drugs/momelotinib/>, <https://onco.cc/drugs/epoetin-alfa/>, <https://onco.cc/technologies/transfusion-support/>, <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/trials/nct04717414/>, <https://onco.cc/trials/nct05320198/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/terms/conditioning-regimen/>, <https://onco.cc/drugs/navitoclax/>, <https://onco.cc/drugs/pelabresib/>, <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/imetelstat/>, <https://onco.cc/trials/nct04468984/>, <https://onco.cc/trials/nct04562389/>, <https://onco.cc/trials/nct04576156/>, <https://onco.cc/trials/nct03441113/> .